Prostaglandin D
Chemoradiotherapy
Cisplatin
Hyperalgesia
Inflammation
Lipocalins
Neuralgia
Peripheral Nervous System Diseases
Prostaglandin D2
Spinal Cord
Journal
The Korean journal of pain
ISSN: 2005-9159
Titre abrégé: Korean J Pain
Pays: Korea (South)
ID NLM: 101528125
Informations de publication
Date de publication:
01 Jan 2021
01 Jan 2021
Historique:
received:
18
09
2020
revised:
24
10
2020
accepted:
28
10
2020
entrez:
31
12
2020
pubmed:
1
1
2021
medline:
1
1
2021
Statut:
ppublish
Résumé
Chemotherapy-induced peripheral neuropathy (CIPN) is a major reason for stopping or changing anticancer therapy. Among the proposed pathomechanisms underlying CIPN, proinflammatory processes have attracted increasing attention. Here we assessed the role of prostaglandin D CIPN was induced by intraperitoneal administration of cisplatin 2 mg/kg for 4 consecutive days using adult male Sprague-Dawley rats. PGD The DP1 and DP2 antagonist AMG 853 and the selective DP2 antagonist CAY10471, but not the DP1 antagonist MK0524, significantly increased the paw withdrawal threshold compared to vehicle controls ( The findings presented here indicate that enhanced PGD
Sections du résumé
BACKGROUND
BACKGROUND
Chemotherapy-induced peripheral neuropathy (CIPN) is a major reason for stopping or changing anticancer therapy. Among the proposed pathomechanisms underlying CIPN, proinflammatory processes have attracted increasing attention. Here we assessed the role of prostaglandin D
METHODS
METHODS
CIPN was induced by intraperitoneal administration of cisplatin 2 mg/kg for 4 consecutive days using adult male Sprague-Dawley rats. PGD
RESULTS
RESULTS
The DP1 and DP2 antagonist AMG 853 and the selective DP2 antagonist CAY10471, but not the DP1 antagonist MK0524, significantly increased the paw withdrawal threshold compared to vehicle controls (
CONCLUSIONS
CONCLUSIONS
The findings presented here indicate that enhanced PGD
Identifiants
pubmed: 33380565
pii: kjp.2021.34.1.27
doi: 10.3344/kjp.2021.34.1.27
pmc: PMC7783857
doi:
Types de publication
Journal Article
Langues
eng
Pagination
27-34Références
Mediators Inflamm. 2012;2012:503128
pubmed: 22791937
Front Mol Neurosci. 2017 May 31;10:174
pubmed: 28620280
J Neurochem. 2008 Mar;104(5):1345-57
pubmed: 18028337
Exp Neurol. 2007 Jan;203(1):42-54
pubmed: 17005179
J Pain. 2013 Dec;14(12):1585-600
pubmed: 24135431
J Neurosci Methods. 1994 Jul;53(1):55-63
pubmed: 7990513
Adv Exp Med Biol. 2003;521:1-21
pubmed: 12617561
Sci Transl Med. 2019 Feb 13;11(479):
pubmed: 30760581
Korean J Pain. 2019 Apr 1;32(2):87-96
pubmed: 31091507
Mol Pain. 2010 Nov 05;6:76
pubmed: 21050491
Expert Opin Investig Drugs. 2016 Sep;25(9):1083-92
pubmed: 27409410
Cancer Treat Rev. 2014 Aug;40(7):872-82
pubmed: 24830939
Life Sci. 1982 Nov 8;31(19):2093-103
pubmed: 6960222
Science. 2000 Mar 17;287(5460):2013-7
pubmed: 10720327
Arch Biochem Biophys. 1988 Feb 1;260(2):521-31
pubmed: 3124755
Pain. 2014 Dec;155(12):2461-70
pubmed: 25261162
Pain. 1994 May;57(2):217-223
pubmed: 7916452
Nat Rev Immunol. 2008 Jan;8(1):59-73
pubmed: 18097448
Brain Behav Immun. 2015 Feb;44:91-9
pubmed: 25220279
J Neuroinflammation. 2020 Jan 22;17(1):30
pubmed: 31969159
Neuroscience. 2003;116(4):1043-52
pubmed: 12617945
Neuropharmacology. 2006 Feb;50(2):165-73
pubmed: 16182321
Pain. 2004 Jul;110(1-2):56-63
pubmed: 15275752
Cancer J. 2007 Nov-Dec;13(6):399-403
pubmed: 18032978
Pharmacol Rep. 2008 Sep-Oct;60(5):735-41
pubmed: 19066421
Lancet Respir Med. 2016 Sep;4(9):699-707
pubmed: 27503237
Glia. 2013 Jun;61(6):943-56
pubmed: 23505121
Br J Pharmacol. 1997 Dec;122(8):1593-604
pubmed: 9422803
Prog Neurobiol. 2001 Jul;64(4):327-63
pubmed: 11275357
Korean J Pain. 2015 Oct;28(4):236-43
pubmed: 26495078
Proc Natl Acad Sci U S A. 1994 Nov 8;91(23):11192-6
pubmed: 7972033
Cytokine. 2012 Jul;59(1):3-9
pubmed: 22537849
J Pain. 2013 Feb;14(2):205-14
pubmed: 23374942
J Neurochem. 1984 Jul;43(1):71-82
pubmed: 6427411